A Milestone for Vision Restoration
For millions of individuals affected by geographic atrophy—the advanced, blinding stage of dry age-related macular degeneration (AMD)—losing central vision often means losing the ability to read, recognize faces, and live independently. Until recently, therapeutic options were largely limited to treatments that slow disease progression rather than reverse existing damage. However, a major regulatory milestone has opened a new chapter for the field of retinal restoration: the PRIMA wireless retinal implant has secured a CE mark, authorizing its commercial availability across 30 European countries.
How the PRIMA System Works
Developed by Science Corporation, the PRIMA system is designed to bypass dead photoreceptor cells and restore functional central form vision. The technology relies on a microscopic photovoltaic chip—measuring just 2 by 2 millimeters and roughly 30 micrometers thick—that is surgically implanted beneath the center of the retina.
This tiny chip acts like a solar panel array with 378 microscopic pixels. It is paired with a specialized pair of glasses equipped with a camera that captures the user's field of view. A small pocket processor refines the video data, and an eye-facing projector beams the image onto the subretinal chip using invisible near-infrared light. The chip converts this light into electrical pulses, stimulating surviving inner retinal neurons and sending visual signals along the optic nerve to the brain. Because the system uses near-infrared light, it does not interfere with whatever natural peripheral vision a patient retains.
Clinical Trial Success and Real-World Impact
European regulatory approval follows encouraging clinical trial data published in The New England Journal of Medicine. In a multi-center study tracking 38 participants across 17 sites, the vast majority of evaluated patients achieved significant visual acuity improvements. Clinical data demonstrated that about 80% of tested patients experienced meaningful gains, with many regaining the ability to read letters, numbers, and words using prosthetic vision. Trial participants have reported engaging in activities previously thought impossible, such as playing crossword puzzles, reading books, and recognizing complex shapes.
Safety evaluations from the trial indicated that while surgical procedures carry inherent risks, most adverse events were manageable and resolved relatively quickly, with overall peripheral vision remaining stable.
Looking Ahead: Expanding Access and Future Research
With the CE mark now secured, the manufacturer is working toward country-specific reimbursement policies and clinical site rollouts across Europe, with commercial implantation expected to begin soon, starting in Germany.
In the United States, the Food and Drug Administration (FDA) has granted the device Breakthrough Device and Humanitarian Use Designations, though it still requires formal review before commercial availability. Researchers and developers are already looking toward future iterations of the technology, aiming to enhance visual acuity, introduce native color perception, and broaden applications for other inherited retinal diseases and degenerative conditions. For patients and families navigating severe vision loss, this regulatory breakthrough represents a tangible step toward restored independence and a future transformed by bio-electronic medicine.